Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All antiandrogen studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchAntiandrogenAntiandrogens (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ ICU admission 80% Improvement Relative Risk Hospitalization 66% Case -1% unadjusted Antiandrogens for COVID-19  Ianhez et al.  Prophylaxis Is prophylaxis with antiandrogens beneficial for COVID-19? Retrospective 12,732 patients in Brazil Lower ICU admission (p=0.26) and hospitalization (p=0.32), not sig. c19early.org Ianhez et al., Dermatologic Therapy, Sep 2020 Favors antiandrogen Favors control

Androgen sensitivity in COVID‐19 and antiandrogens: Prospective data are still needed

Ianhez et al., Dermatologic Therapy, doi:10.1111/dth.14166
Sep 2020  
  Post
  Facebook
Share
  Source   PDF   All   Meta
7th treatment shown to reduce risk in September 2020
 
*, now known with p = 0.000000056 from 49 studies.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,100+ studies for 60+ treatments. c19early.org
Retrospective survey of 41,529 participants, including 571 on antiandrogen therapy, showing no significant association between antiandrogen use and COVID-19 incidence, hospitalization, or ICU admission/mechanical ventilation.
risk of ICU admission, 79.7% lower, RR 0.20, p = 0.26, treatment 1 of 17 (5.9%), control 28 of 357 (7.8%), adjusted per study, odds ratio converted to relative risk, multivariable.
risk of hospitalization, 65.7% lower, RR 0.34, p = 0.32, treatment 2 of 17 (11.8%), control 64 of 357 (17.9%), adjusted per study, odds ratio converted to relative risk, multivariable.
risk of case, 1.4% higher, RR 1.01, p = 0.90, treatment 17 of 571 (3.0%), control 357 of 12,161 (2.9%), unadjusted, total count not provided, estimated from percentage.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Ianhez et al., 3 Sep 2020, retrospective, Brazil, peer-reviewed, 4 authors. Contact: ianhez@hotmail.com.
This PaperAntiandrogensAll
Abstract: Title: Androgen sensitivity in COVID-19 and antiandrogens: prospective data are still needed. Author´s list: Mayra Ianhez1, Paulo Müller Ramos2, Andy Goren3, Hélio Amante Miot2 Author´s Affiliations: 1 Department of Tropical Medicine and Dermatology, Federal University of Goiás, Goiânia - GO, Brazil Address: 1a Avenida, s/n, St Leste Universitário, CEP: 74605-020, Goiânia-GO, Brazil 2 Department of Dermatology and Radiotherapy, São Paulo State University – UNESP, Botucatu - SP, Brazil Address: Av. Prof. Mário Bairro: UNESP 18618687, Botucatu, SP - Brasil 3 Rubens Guimarães Campus Montenegro, s/n de Botucatu Applied Biology, Irvine - California, USA Address: 17780 Fitch, Irvine, CA 92614, Estados Unidos Acknowledgements: none Keywords: alopecia; antiandrogen; SARS-CoV-2; COVID-19; therapy-systemic Running head: Antiandrogens in COVID-19 Funding: None Correspondence: Mayra Ianhez, MD, PhD Department of Tropical Medicine and Dermatology Federal University of Goiás This article is protected by copyright. All rights reserved. 1ª avenida, s/ no, Setor Leste Universitário, Goiânia-GO CEP: 74605-020 Email: (*ianhez@hotmail.com) Phone/FAX: +55 62 985315443 Men are disproportionately affected by COVID-19 and have an increased risk of ICU admittance as well as mortality. In contrast, prepubescents appear to be largely protected from COVID-19 severe symptoms1. The androgen receptor regulates the transcription of the transmembrane protease, serine 2 (TMPRSS2), and angiotensin converting enzyme 2 (ACE2) which are required for the COVID19 infectivity; thus, raising the hypothesis of androgen sensitivity as a risk factor2,3. The recent association of androgenetic alopecia (AGA) with COVID-19 severity strengthens the androgen theory2. Testosterone levels are low not only in prepubescents but also in elderly men4 and recent observations point out that disease severity may be best correlated with specific gene loci, rather than ACE2 or TMPRSS2 receptors5. Furthermore, serum androgens do not always correlate with tissue androgens or androgen mediated disease. For example, AGA and prostate cancer can be exacerbated by elevated tissue androgen in genetically predisposed patients6. In order to elucidate the effect of androgens on COVID-19 outcomes, some epidemiological studies were conducted. Since TMPRSS2 are expressed in the lungs, the use of antiandrogens or androgen-depleting therapies (ADT), This article is protected by copyright. All rights reserved. currently used for prostate cancer, represent an appealing target for prevention or treatment of COVID-19 4. An Italian study compared infectivity and outcomes of COVID-19 in prostate cancer patients treated with or without ADT (androgen deprivation therapies). The study concluded that ADT was associated with reduced risk of infection and with reduced COVID-19 disease burden7; however, to-date, no large epidemiological study attempted to evaluate the potential protective role of diverse antiandrogens in COVID-19 infection. To gather large scale data, we performed a population survey through snowball sampling. Participants were invited to complete an electronic questionnaire comprising baseline demographic, COVID-19 status (never, suspected or confirmed), disease severity (home, hospitalization without mechanical ventilation, intensive care unit/mechanical ventilation – ICU/MV), use of antiandrogen therapy (ADT for prostate cancer, finasteride, dutasteride, flutamide, bicalutamide,..
{ 'DOI': '10.1111/dth.14166', 'ISSN': ['1396-0296', '1529-8019'], 'URL': 'http://dx.doi.org/10.1111/dth.14166', 'alternative-id': ['10.1111/dth.14166'], 'assertion': [ { 'group': {'label': 'Publication History', 'name': 'publication_history'}, 'label': 'Received', 'name': 'received', 'order': 0, 'value': '2020-07-13'}, { 'group': {'label': 'Publication History', 'name': 'publication_history'}, 'label': 'Accepted', 'name': 'accepted', 'order': 1, 'value': '2020-08-02'}, { 'group': {'label': 'Publication History', 'name': 'publication_history'}, 'label': 'Published', 'name': 'published', 'order': 2, 'value': '2020-09-03'}], 'author': [ { 'ORCID': 'http://orcid.org/0000-0003-3604-3128', 'affiliation': [ { 'name': 'Department of Tropical Medicine and Dermatology Federal ' 'University of Goiás Goiânia Goiás Brazil'}], 'authenticated-orcid': False, 'family': 'Ianhez', 'given': 'Mayra', 'sequence': 'first'}, { 'ORCID': 'http://orcid.org/0000-0002-1561-414X', 'affiliation': [ { 'name': 'Department of Dermatology and Radiotherapy São Paulo State ' 'University—UNESP Botucatu São Paulo Brazil'}], 'authenticated-orcid': False, 'family': 'Ramos', 'given': 'Paulo Müller', 'sequence': 'additional'}, { 'ORCID': 'http://orcid.org/0000-0002-8190-2289', 'affiliation': [{'name': 'Applied Biology Irvine CA USA'}], 'authenticated-orcid': False, 'family': 'Goren', 'given': 'Andy', 'sequence': 'additional'}, { 'ORCID': 'http://orcid.org/0000-0002-2596-9294', 'affiliation': [ { 'name': 'Department of Dermatology and Radiotherapy São Paulo State ' 'University—UNESP Botucatu São Paulo Brazil'}], 'authenticated-orcid': False, 'family': 'Miot', 'given': 'Hélio Amante', 'sequence': 'additional'}], 'container-title': 'Dermatologic Therapy', 'container-title-short': 'Dermatologic Therapy', 'content-domain': {'crossmark-restriction': True, 'domain': ['onlinelibrary.wiley.com']}, 'created': {'date-parts': [[2020, 8, 9]], 'date-time': '2020-08-09T16:41:25Z', 'timestamp': 1596991285000}, 'deposited': { 'date-parts': [[2022, 12, 23]], 'date-time': '2022-12-23T17:59:02Z', 'timestamp': 1671818342000}, 'indexed': {'date-parts': [[2024, 1, 10]], 'date-time': '2024-01-10T14:21:34Z', 'timestamp': 1704896494062}, 'is-referenced-by-count': 2, 'issue': '6', 'issued': {'date-parts': [[2020, 9, 3]]}, 'journal-issue': {'issue': '6', 'published-print': {'date-parts': [[2020, 11]]}}, 'language': 'en', 'license': [ { 'URL': 'http://onlinelibrary.wiley.com/termsAndConditions#vor', 'content-version': 'vor', 'delay-in-days': 0, 'start': { 'date-parts': [[2020, 9, 3]], 'date-time': '2020-09-03T00:00:00Z', 'timestamp': 1599091200000}}, { 'URL': 'http://doi.wiley.com/10.1002/tdm_license_1.1', 'content-version': 'tdm', 'delay-in-days': 0, 'start': { 'date-parts': [[2020, 9, 3]], 'date-time': '2020-09-03T00:00:00Z', 'timestamp': 1599091200000}}], 'link': [ { 'URL': 'https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fdth.14166', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://onlinelibrary.wiley.com/doi/pdf/10.1111/dth.14166', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://onlinelibrary.wiley.com/doi/full-xml/10.1111/dth.14166', 'content-type': 'application/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://onlinelibrary.wiley.com/doi/pdf/10.1111/dth.14166', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'member': '98', 'original-title': [], 'prefix': '10.1155', 'published': {'date-parts': [[2020, 9, 3]]}, 'published-online': {'date-parts': [[2020, 9, 3]]}, 'published-print': {'date-parts': [[2020, 11]]}, 'publisher': 'Hindawi Limited', 'reference': [ { 'article-title': 'Gender differences in patients with COVID‐19: focus on severity and ' 'mortality', 'author': 'Jian‐Min J', 'issue': '152', 'journal-title': 'Front Public Health', 'key': 'e_1_2_3_2_1', 'volume': '8', 'year': '2020'}, {'DOI': '10.1002/ddr.21688', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_3_3_1'}, { 'article-title': 'Androgen regulates SARS‐CoV‐2 receptor levels and is associated with ' 'severe COVID‐19 symptoms in men', 'author': 'Ghazizadeh Z', 'journal-title': 'bioRxiv', 'key': 'e_1_2_3_4_1', 'year': '2020'}, { 'DOI': '10.1016/j.metabol.2020.154252', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_3_5_1'}, {'DOI': '10.1056/NEJMoa2020283', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_3_6_1'}, {'DOI': '10.1007/s00403-012-1265-x', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_3_7_1'}, { 'DOI': '10.1016/j.annonc.2020.04.479', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_3_8_1'}, {'DOI': '10.1128/JVI.00649-19', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_3_9_1'}, { 'DOI': '10.1371/journal.ppat.1005374', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_3_10_1'}], 'reference-count': 9, 'references-count': 9, 'relation': {}, 'resource': {'primary': {'URL': 'https://onlinelibrary.wiley.com/doi/10.1111/dth.14166'}}, 'score': 1, 'short-title': [], 'source': 'Crossref', 'subject': ['Dermatology', 'General Medicine'], 'subtitle': [], 'title': 'Androgen sensitivity in\n' ' <scp>COVID</scp>\n' ' ‐19 and antiandrogens: Prospective data are still needed', 'type': 'journal-article', 'update-policy': 'http://dx.doi.org/10.1002/crossmark_policy', 'volume': '33'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit